Abstract

We investigated the real dual antiplatelet therapy (DAPT) duration after the drug-eluting stent (DES) treatment in China. 9,919 consecutive patients with DES implantation were enrolled. The follow-up DAPT cessation and associated factors with different DAPT durations were analyzed. The proportion of patients with DAPT coverage at 1-year follow-up was 97.3%, and decreased to 30.1% for 2-years. The distribution of DAPT duration (<1 year, =1 year and >1 year) was not significantly different among patients presented with AMI versus non-AMI (p=0.41), and new-generation DES versus first-generation DES (p=0.54). The multivariable analysis indicated some independent predictors of prolonging DAPT duration, including TVR (OR 2.50, 95% CI 2.04-3.06, p<0.001), stent numbers (OR 1.10, 95% CI 1.05-1.15, p<0.001), and previous coronary artery bypass grafting (OR 0.76, 95% CI 0.61-0.96, p=0.02). Other clinical factors such as the increased risks of bleeding and high ischemic risks were not associated with DAPT duration. 1-year DAPT after DES was applied to 97.3% in China. However, the DAPT duration after 1 year was not adjusted according to the patients’ bleeding situation and ischemic risks.

Highlights

  • Dual antiplatelet therapy (DAPT), i.e., aspirin in combination with a P2Y12 antagonist, is an essential component of the treatment of patients undergoing percutaneous coronary intervention (PCI) especially with the drug-eluting stent (DES) [1]

  • The data coming from the PARIS registry suggested that the proportions of patients with DAPT coverage after the DES implantation at 1-year and 2-year follow-up were 76.7% and 42.7%, respectively in 15 clinical sites in US and Europe [13]

  • The patients were divided into 3 groups according to DAPT duration: 1 year (>13 months)

Read more

Summary

Introduction

Dual antiplatelet therapy (DAPT), i.e., aspirin in combination with a P2Y12 antagonist, is an essential component of the treatment of patients undergoing percutaneous coronary intervention (PCI) especially with the drug-eluting stent (DES) [1]. A minimum DAPT duration of 12 months after DES implantation had been recommended by guidelines, irrespective of reported clinical research results [1,2]. A reduced DAPT duration has been considered safe and with the reduced risk of bleeding complications [4,5,6,7], the ST longer than 12 months after the DES implantation was still observed [8]. Updated guidelines with adjusted DAPT duration after DES implantation has been recommended according to the patients’ bleeding and ischemic risks [9,10,11]. The DAPT duration after the DES implantation is more complicated, determined by both physicians’ comprehension of the complex guidelines and the patients’ compliance [12]. We analyzed a large amount of cases in the biggest cardiovascular center in China to investigate the DAPT duration and identify associated factors after the DES implantation

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call